Combination treatment for HER2-positive cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two targeted drugs (RC48 and QL1706) for people with cervical cancer that has returned after initial treatment. It focuses on cancers that have a protein called HER2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have cervical cancer (squamous cell, adenocarcinoma, or mixed type) that has come back or spread after first-line treatment.
- Your tumor has a protein called HER2 (at least 1+ on a test).
- You can provide a sample of your tumor for testing.
- You have at least one measurable tumor on scans.
- You are generally well enough to do daily activities (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment (QL706) combined with chemotherapy, with or without bevacizumab, for cervical cancer that has stopped responding to previous immunotherapy. It aims to find a better option for patients whose disease has progressed after anti-PD-1/PD-L1 therapy.
This trial tests a combination of two drugs, RC48 and Tislelizumab, for people with recurrent cervical cancer whose tumors have a protein called HER2. The goal is to see if this treatment can help when previous therapy has stopped working.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
This trial tests a new drug, RC48, for people with ovarian cancer that came back after responding well to platinum chemotherapy. RC48 targets the HER2 protein on cancer cells, which may stop the tumor from growing. Researchers want to see if it's safe and works better than current options.
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
This trial tests a combination of two drugs—SKB264 and QL1706—for women with cervical cancer that has come back or spread and is not curable with standard treatments. The goal is to see if this new combination can help shrink tumors or slow the disease.
Hear when a new Recurrent Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.